Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18855496 | 1.00 | MEN1 (0.38) | MEN1KMT2AMAPTCYP2C19CYP3A4 | |
| SCHEMBL27334574 | 0.84 | PTPN1 (0.42) | MEN1KMT2AMAPTCYP2C19CYP3A4 | |
| SCHEMBL20635012 | 0.82 | MEN1 (0.49) | MEN1KMT2AMAPTCYP2C19CYP3A4 | |
| SCHEMBL7751495 | 0.80 | MAPT (0.36) | MEN1KMT2AMAPTCYP2C19CYP3A4 | |
| SCHEMBL7751489 | 0.80 | MAPT (0.36) | MEN1KMT2AMAPTCYP2C19CYP3A4 | |
| SCHEMBL21158099 | 0.77 | KMT2A (0.47) | MEN1KMT2AMAPTCYP2C19GAA | |
| SCHEMBL15133879 | 0.77 | FOLH1 (0.42) | MEN1KMT2AMAPTFOLH1LMNA | |
| SCHEMBL7662999 | 0.77 | MEN1 (0.61) | MEN1KMT2AMAPTFOLH1LMNA | |
| SCHEMBL7663002 | 0.77 | MEN1 (0.61) | MEN1KMT2AMAPTFOLH1LMNA | |
| SCHEMBL19662368 | 0.76 | FOLH1 (0.48) | MEN1KMT2AMAPTFOLH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | MEN1 4419/4885KMT2A 1216/4885MAPT 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.